MOD B
Alternative Names: MOD-B; MOD-B: Research programme - AlivexisLatest Information Update: 07 May 2024
At a glance
- Originator Modulus Discovery
- Developer Alivexis
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammation
- Research Cancer
Most Recent Events
- 26 Apr 2024 Preclinical trials in Inflammation in Japan (unspecified route) prior to April 2024 (PeptiDream Pipeline, April 2024)
- 13 Apr 2023 MOD B is available for licensing as of 13 Apr 2023. https://modulusdiscovery.com/pipeline/ (Modulus Discovery pipeline; April 2023)
- 13 Apr 2023 Early research in Cancer in Japan (unspecified route) (Modulus Discovery pipeline; April 2023)